A VISIONaerie® approach
We discover, develop, and commercialize first-in-class therapies for the treatment of patients with glaucoma, retinal diseases and other diseases of the eye
News Highlights
Aerie Pharmaceuticals Announces Positive Topline Results for Netarsudi... Aerie Pharmaceuticals Announces the Appointment of David A. Hollander,... Aerie Pharmaceuticals Completes Enrollment in the Phase 2 Trial of AR-...STOCK Quote
NASDAQ: AERI
$18.50USD
Nov 14, 10:52 AM ET
VOLUME
119,986
DAY LOW/HIGH
$18.36/$18.96
52 - WEEK LOW/HIGH
$17.51/$50.10
